CAS: 94-78-0; 3-(Phenylazo)-2,6-Pyridinediamine

上下游产品

CAS号136-40-3 盐酸非那吡啶 | CAS号100-34-5 氯化重氮苯 | CAS号4318-79-0 2,3,6-三氨基吡啶 | CAS号29817-76-3 Benzenesulfonam...

📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于水体系中,化学反应生成 非那吡啶
参考文献:Note On Bacteriostatic Azo Compounds
标题:Note On Bacteriostatic Azo Compounds
摘要:
DOI:10.1021/ja01323A019

专利信息

专利号:US-2023313255-A1
优先权日:2020-07-15
标题:Massively Parallel Enzymatic Synthesis of Polynucleotides
发明人：HORGAN ADRIAN; LACHAIZE HENRI; VERARDO DOMIANO; GODRON XAVIER
权利人:DNA SCRIPT
摘要:The invention is directed to methods and compositions for inkjet assisted synthesis of a plurality of polynucleotides at reaction sites on a substrate using template-free polymerases, such as, terminal deoxynucleotidyl transferases (TdTs). Compositions of the invention include formulations of synthesis reagents for inkjet delivery including, but not limited to, TdT coupling reaction buffers and 3′-O-protected dNTP monomers.

专利号:US-2008125587-A1
优先权日:2006-05-25
标 题 :Synthesis of triazole compounds that modulate HSP90 activity
发明人：CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
权利人:CHIMMANAMADA DINESH U; LEE CHI-WAN; JAMES DAVID; ZHANG SHIJIE; YING WEIWEN; CHAE JUNGHYUN; PRZEWLOKA TERESA
摘要:The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: n n n n n n n n n n with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. n In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) n n n n n n n n n n with an oxidizing agent, thereby producing a compound of formula (IA). n The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: n n n n n n n n n n or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: n n n n n n n n n n in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

专利号:US-6723798-B1
优先权日:2000-08-28
标 题:Resins having vinyl ether linker for the solid phase organic synthesis
发明人：YOO SUNGEUN; GONG YOUNGDAE; SEO JINSOO
权利人:KOREAN RES INST OF CHEMICAL TE
摘要:The present invention relates to a resin having a vinyl ether linker and more particularly, to a resin having a vinyl ether linker expressed by formula (I), useful for the synthesis of compounds having hetero atoms such as alcohol, thiol, imidazole, triazole and tetrazole by employing combinatorial chemical synthesis on solid supports.

专利号:US-5446158-A
优先权日:1989-01-11
标题:Process for synthesis of FK-506 and tricarbonyl intermediates
发明人：JONES TODD K; MILLS SANDER G; ASKIN DAVID; REAMER ROBERT A; DESMOND RICHARD; TSCHAEN DAVID M; VOLANTE RALPH P; SHINKAI ICHIRO
权利人:MERCK & CO INC
摘要:A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.

专利号:US-2011195450-A1
优先权日:2005-09-27
标 题 :In Vitro Protein Synthesis Systems for Membrane Proteins that Include Adolipoproteins and Phospholipid Adolipoprotein Particles
发明人：KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
权利人:LIFE TECHNOLOGIES CORP
摘要:In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.

专利号:WO-2007038755-A1
优先权日:2005-09-27
标 题:In vitro protein synthesis systems for membrane proteins that include apolipoproteins and phospholipid-apolipoprotein particles
发明人：KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
权利人:INVITROGEN CORP; KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
摘要:In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.